• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Nephrology

Prediction of individuals at high risk of chronic kidney disease during treatment with lithium for bipolar disorder

byDavy LauandAlex Chan
May 5, 2021
in Nephrology, Psychiatry
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

RELATED REPORTS

Cystatin C-based equation without race or sex improves accuracy of GFR estimation

Empagliflozin use is associated with slower progression of chronic kidney disease

Lecanemab may slow cognitive decline in early Alzheimer’s disease

1. Individuals with bipolar disorder at higher risk of chronic kidney disease after lithium initiation include patients who are young, female, obese, have high LDL cholesterol, and have lower baseline eGFR levels.

Evidence Rating Level: 2 (Good)

Lithium is the standard first-line treatment for bipolar disorder worldwide. However, due to its narrow therapeutic window and potential adverse effects, its use has waned. A rare adverse effect of lithium is irreversible kidney failure, with a prevalence of 0.23% compared to 0.11% for the general population. The current study created a model to classify individuals as high-risk or low-risk for developing chronic kidney disease (CKD) after initiation of lithium treatment. The study population consisted of patients aged 16 and over with a diagnosis of bipolar disorder for which lithium was prescribed, had a normal or close to normal kidney function at baseline, and had three estimated glomerular filtration rates (eGFRs) measured after lithium initiation. Patients were taken from two databases, 1609 from the Aurum database and 934 from the Gold database for external validation. For the Aurum cohort, 24.92% of patients developed stage 3a or greater CKD. Using eGFR trajectories to define the high-risk and low-risk group, 87.96% in the high-risk developed stage 3a or greater CKD, and 16.43% in the low-risk. 11.87% of the cohort was determined to be high-risk. The high-risk group was more likely to be younger, female, obese, have a high LDL cholesterol, and have a lower baseline eGFR. The same factors were found in the high-risk group for the Gold cohort. Overall, the study developed a model that classified around 10% of patients to be at higher risk of kidney injury after lithium initiation, which may have implications for alleviating concern around lithium use for patients identified as low-risk.

Click to read the study in BMC Medicine

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Bipolar Disorderlithiumnephrologypsychiatry
Previous Post

#VisualAbstract: Sacituzumab govitecan increased survival in metastatic triple-negative breast cancer

Next Post

Convalescent plasma transfusion provides mortality benefit in early COVID-19 disease stage

RelatedReports

Intravenous contrast may not increase risk of acute kidney injury
Chronic Disease

Cystatin C-based equation without race or sex improves accuracy of GFR estimation

February 3, 2023
Fish oil and aspirin did not reduce arteriovenous fistula failure: The FAVOURED trail
Cardiology

Empagliflozin use is associated with slower progression of chronic kidney disease

January 26, 2023
Free alternatives comparable to Mini-Mental State Examination
Chronic Disease

Lecanemab may slow cognitive decline in early Alzheimer’s disease

January 10, 2023
Mindfulness-based therapy associated with improvement in quality of life for PTSD patients
Chronic Disease

Intensive outpatient prolonged exposure effective for combat related posttraumatic stress disorder

January 9, 2023
Next Post
Novel coronavirus identified from patients with pneumonia in Wuhan, China

Convalescent plasma transfusion provides mortality benefit in early COVID-19 disease stage

#VisualAbstract: Pembrolizumab improves long-term survival in patients with stage III melanoma

#VisualAbstract: Pembrolizumab improves long-term survival in patients with stage III melanoma

Quick Take: Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent)

Sonelokimab 120 mg or less showed significant clinical benefit over placebo in patients with plaque psoriasis

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Dual antiplatelet therapy discontinued 9 months after percutaneous coronary intervention associated with improved morbidity and mortality
  • Concordance of diagnosis of autism spectrum disorder made by pediatricians vs multidisciplinary specialist teams
  • Cystatin C-based equation without race or sex improves accuracy of GFR estimation
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options